Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Prevention of Chronic Migraine in Chinese Patients
CTR20161050Phase 3Suspended
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in chronic migraine, sponsored by AbbVie Inc.. Started Jan 2017; status: suspended.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on CTR20161050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20161050.